Report period | 2020 |
---|---|
End date of the reporting period | |
Capitalization, $ | |
Capitalization, $ | |
Enterprise Value | |
Book Value | |
Shareholders Book Value | |
Current liabilities | |
Noncurrent liabilities | |
Total liabilities | |
Cash and cash equivalents | |
Net debt | |
Assets | |
Total ordinary shares | |
Ordinary share price |
Report period | 2020 |
---|---|
End date of the reporting period | |
Sales | |
Operation Income | |
Earnings | |
Shareholders earnings | |
EBITDA | |
Operation Cashflow | |
Capital expenditure | |
Free Cash Flow | |
EPS |
Report period | 2020 |
---|---|
P/E | |
E/P | |
P/B | |
P/S | |
P/FCF | |
L/A | |
Net Debt/EBITDA | |
EV/EBITDA |
Report period | 2020 |
---|---|
ROA | |
ROS | |
EBITDA Margin | |
Operating margin |
Company name | Pandion Therapeutics |
---|---|
Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology |
Business address | /companies/PAND:US |
Website | investors.pandiontx.com |
Information disclosure | www.sec.gov |